Tags

Type your tag names separated by a space and hit enter

Choledocholithiasis

Choledocholithiasis is a topic covered in the 5-Minute Clinical Consult.

To view the entire topic, please or purchase a subscription.

Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Explore these free sample topics:

Medicine Central

-- The first section of this topic is shown below --

Basics

Description

  • Stones in common bile duct (CBD)
  • Several types: cholesterol (majority), calcium bilirubinate or pigment, and mixed stones
  • System(s) affected: gastrointestinal; hepatobiliary
  • Synonym(s): CBD stones; CBD calculi

Epidemiology

Incidence
  • Gallstone disease affects >20 million Americans (14.2 million females, 6.3 million males).
    • Choledocholithiasis noted in 7–12% of patients undergoing cholecystectomy for symptomatic gallstones
    • Choledocholithiasis noted in 18–33% of patients with acute biliary pancreatitis
  • Incidence increases with age (30–50% of patients >60 years with gallstones have concurrent CBD stones):
    • Patients with choledocholithiasis are, on average, 10 years older than those with cholelithiasis.
  • Internationally, incidence is increased due to parasitic infections (e.g., Ascaris lumbricoides).
  • Associated with chronic conditions such as dyslipidemia, obesity, cardiovascular disease, as well as increased risk of mortality

Prevalence
  • Symptomatic gallstone disease affects 10% of the U.S. population, leading to ~700,000 cholecystectomies at an annual cost of ~$6.5 billion.
  • Twice as common among women
  • Increased prevalence among Hispanics, Asians, Native Americans

Etiology and Pathophysiology

  • CBD stones may be primary or secondary:
    • Primary stones form within the biliary tract with bile stasis or chronic bactibilia.
    • Secondary stones (more common) form within the gallbladder and migrate to the biliary tree.
  • Stones may migrate to the duodenum or remain in the CBD (due to small diameter of Vater papilla). Not all CBD stones are symptomatic.
  • Obstruction leads to jaundice. Biliary stasis can trigger infection (e.g., ascending cholangitis).
  • Dysfunction/obstruction of the CBD and/or main pancreatic duct can trigger acute pancreatitis.
  • Chronic hemolytic states increase the risk for gallstone formation.
  • Formation of de novo pigment stones can result from:
    • Dilated, sclerosed, or strictured ducts (e.g., recurrent cholangitis)
    • Hepatobiliary parasitism (A. lumbricoides or Clonorchis sinensis)

Genetics
  • MDR3 defects may predispose to biliary sludge, cholelithiasis, cholestasis of pregnancy, and subsequent choledocholithiasis.
  • Variants of UGT1A1 responsible for bilirubin conjugation may increase cholesterol and pigment gallstone formation.
  • Hepatobiliary cholesterol hemitransporter ABCG8 variant p.D19H doubles the odds of gallstone recurrence after cholecystectomy.
  • LITH genes are thought to increase susceptibility to development of gallstones. Studies in mice show this class of genes creates a lithogenic environment by altering various lipid transporters, nuclear hormone receptors, and enzymes.

Risk Factors

  • Obesity; high caloric diet, low-fiber diet
  • Rapid weight loss (>25% of original weight, especially after bariatric surgery) or prolonged fasting
  • Gender (females > males)
  • Family history
  • Cirrhosis
  • Crohn disease
  • Gallbladder stasis: spinal cord injury, somatostatin
  • Drugs (octreotide, thiazide diuretics)
  • Pancreatitis
  • Chronic estrogen exposure
  • Prior cholecystectomy:
    • <2 years prior: Consider retained stone.
    • >2 years prior: Consider recurrent stone.

General Prevention

  • Maintain healthy weight and lifestyle. Avoid rapid weight loss.
  • Consider UDCA therapy in LPAC syndrome.

Commonly Associated Conditions

  • Cholelithiasis, cholecystitis, cholangitis
  • Gallstone pancreatitis

-- To view the remaining sections of this topic, please or purchase a subscription --

Citation

Stephens, Mark B., et al., editors. "Choledocholithiasis." 5-Minute Clinical Consult, 27th ed., Wolters Kluwer, 2019. Medicine Central, im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/116128/all/Choledocholithiasis.
Choledocholithiasis. In: Stephens MB, Golding J, Baldor RA, et al, eds. 5-Minute Clinical Consult. 27th ed. Wolters Kluwer; 2019. https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/116128/all/Choledocholithiasis. Accessed July 21, 2019.
Choledocholithiasis. (2019). In Stephens, M. B., Golding, J., Baldor, R. A., & Domino, F. J. (Eds.), 5-Minute Clinical Consult. Available from https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/116128/all/Choledocholithiasis
Choledocholithiasis [Internet]. In: Stephens MB, Golding J, Baldor RA, Domino FJ, editors. 5-Minute Clinical Consult. Wolters Kluwer; 2019. [cited 2019 July 21]. Available from: https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/116128/all/Choledocholithiasis.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Choledocholithiasis ID - 116128 ED - Stephens,Mark B, ED - Golding,Jeremy, ED - Baldor,Robert A, ED - Domino,Frank J, BT - 5-Minute Clinical Consult, Updating UR - https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/116128/all/Choledocholithiasis PB - Wolters Kluwer ET - 27 DB - Medicine Central DP - Unbound Medicine ER -